DCM
ORKA

DAFNA Capital Management’s Oruka Therapeutics ORKA Stock Holding History

DAFNA Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-376
Closed -$653K – 91
2015
Q2 		$653K Buy
+376
New +$494K 0.55% 47

Other funds holding ORKA

VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DAFNA Capital Management's ORKA Position: Q3 2015 in Review

DAFNA Capital Management sold out of Oruka Therapeutics (ORKA) in Q3 2015, closing a stake of 376 shares — an estimated $653K sold.

DAFNA Capital Management first reported a position in ORKA in Q2 2015 and held it in 1 quarter. The position peaked at $653K in Q2 2015. 13 funds tracked by Wall St. Rank hold ORKA as of Q3 2015.

  • DAFNA Capital Management reported no remaining Oruka Therapeutics position as of Q3 2015 after selling out during the quarter.
  • DAFNA Capital Management sold 376 Oruka Therapeutics shares in Q3 2015, an estimated $653K.
  • DAFNA Capital Management first reported a position in Oruka Therapeutics in Q2 2015 and held it in 1 quarter.
  • DAFNA Capital Management's Oruka Therapeutics position peaked at $653K in Q2 2015.
  • 13 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2015.

Based on DAFNA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.